Evotec SE (EVO)
5.22
-2.43
(-31.76%)
USD |
NASDAQ |
Apr 24, 12:25
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 1.850B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -21.77% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 2.249 |
Price to Book Value | 1.532 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.5161 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 74.02% |
Profile
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The EVT Execute segment, about 75% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment, about 25% of sales, develops proprietary drug discovery programs and assets, which can lead to partnerships with clients. As of 2022, the company has almost 5,000 employees and 17 production sites mainly in Europe and the United States. |
URL | https://www.evotec.com |
Investor Relations URL | N/A |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Life Sciences Tools & Services |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Apr. 24, 2024 |
Last Earnings Release | Apr. 24, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The EVT Execute segment, about 75% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment, about 25% of sales, develops proprietary drug discovery programs and assets, which can lead to partnerships with clients. As of 2022, the company has almost 5,000 employees and 17 production sites mainly in Europe and the United States. |
URL | https://www.evotec.com |
Investor Relations URL | N/A |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Life Sciences Tools & Services |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Apr. 24, 2024 |
Last Earnings Release | Apr. 24, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |